Shop Research Compounds
Home / Shop / retatrutide-5mg
retatrutide-5mg research product by Crystal Peptides
Fat Loss & Metabolism

retatrutide-5mg

5mg/vial

Investigational metabolic peptide studied around GLP-1, GIP, and glucagon receptor pathways.

€55,00
Third-party testedCOA availableEU shippingResearch only
For in-vitro laboratory research only. Not for human or veterinary use.This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.
Research intelligence

Research context for Retatrutide 5mg

This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.

Product research overview

Retatrutide is an investigational peptide agonist designed to engage GIP, GLP-1, and glucagon receptors. It remains under clinical investigation; this vial is presented only as research reference material and not as a pharmaceutical product.

MaterialTriple receptor agonist
Primary areaIncretin and metabolic signaling
EvidenceClinical investigation plus preclinical mechanism
CatalogFat Loss & Metabolism

Mechanism & pathway context

  • Literature describes coordinated agonism at GIPR, GLP-1R, and GCGR, three class B G-protein-coupled receptors involved in metabolic signaling.
  • Phase 2 studies provide investigational human context, while structure and receptor-bias work continues to refine the mechanism.

GLP-1 receptor

Incretin-linked signaling and metabolic endpoints.

GIP receptor

Glucose-dependent insulinotropic pathway research.

Glucagon receptor

Hepatic and energy-balance signaling models.

Multi-agonist design

Receptor potency, bias, and integrated pathway studies.

What researchers study

  • Receptor activation and signaling bias
  • Metabolic biomarkers in controlled studies
  • Energy-balance endpoints in model systems
  • Safety and tolerability in registered clinical investigation

Current evidence snapshot

Evidence areaResearch contextStrengthNotes
Receptor pharmacologyPreclinical and structural studiesPreclinicalTriple-agonist activity is mechanistically characterized.
Clinical investigationPhase 2 trialsEarly / investigationalResults do not constitute approval or product equivalence.
Approved useRegulatory statusLimitedRetatrutide remains investigational.

Limitations & safety boundaries

  • Retatrutide is investigational and is not an approved medicine.
  • Evidence may be limited to cell, tissue, or animal models and may not translate to humans.
  • No dosing, administration, preparation, or clinical guidance is provided.
  • Researchers and buyers are responsible for institutional requirements and applicable local laws.

For in-vitro laboratory research only. Not for human or veterinary use.